Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid assays boosted revenues to previously unanticipated heights and each new wave and variant provided new opportunities for innovation.
As the pandemic recedes, the demand for these assays has inevitably crashed, leaving some players wondering if it was all a dream. For others, though, the return to a more normal market is a welcome relief as treatments and surgeries that were halted due to Covid begin to ramp up again.
But what does this mean in the longer term? While a post-Covid reset was inevitable, has the pandemic fundamentally changed the shape of the world of medtech?
Find out now. Download the full report for data-driven insights based on Evaluate Medtech consensus forecasts to 2028.
